Camilla Sandberg
Director Ejecutivo en MIRIS HOLDING AB .
Cargos activos de Camilla Sandberg
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| MIRIS HOLDING AB | Director Ejecutivo | 04/10/2016 | - |
| NEXTCELL PHARMA AB | Director/Miembro de la Junta | 01/01/2017 | - |
| Independent Dir/Board Member | 01/01/2017 | - | |
| MONIVENT AB | Director/Miembro de la Junta | - | - |
| Independent Dir/Board Member | - | - |
Historial de carrera de Camilla Sandberg
Antiguos cargos conocidos de Camilla Sandberg.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
BioLamina AB
 BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Ventas & Marketing | - | - |
Formación de Camilla Sandberg.
| University of Oslo | Masters Business Admin |
Estadísticas
Internacional
| Suecia | 5 |
| Noruega | 2 |
Operativa
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectorial
| Health Technology | 4 |
| Electronic Technology | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MIRIS HOLDING AB | Electronic Technology |
| NEXTCELL PHARMA AB | Health Technology |
| MONIVENT AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Camilla Sandberg
- Experiencia
